Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Januar 2016 16:05 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Provides Review of 2015 and Projected Future Milestones

EMERYVILLE, Calif., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today is providing a summary of 2015 corporate highlights and planned future milestones. ...
06. Januar 2016 22:07 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Announces Pricing of Public Offering of Common Stock

EMERYVILLE, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common...
05. Januar 2016 07:15 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer 2,500,000 shares of its common stock in an underwritten...
23. Dezember 2015 06:00 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease

EMERYVILLE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that its Phase 3 EASE LID clinical trial evaluating the company’s investigational...
22. Dezember 2015 17:23 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas to Host Conference Call and Webcast to Provide Company Update

Call Scheduled for Wednesday, December 23 at 8:00 a.m. Eastern Time EMERYVILLE, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory...
14. Dezember 2015 16:05 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Completes Enrollment of Its Phase 3 EASE LID 3 Study Evaluating ADS-5102 for Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson’s Disease

EMERYVILLE, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of enrollment in its Phase 3 EASE LID 3 study. EASE LID 3 is a...
17. November 2015 16:05 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference

EMERYVILLE, Calif., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will...
12. November 2015 16:05 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Reports Third Quarter 2015 Financial Results

EMERYVILLE, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the third quarter of 2015. The company reported a net...
27. Oktober 2015 16:05 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference

EMERYVILLE, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas...
12. Oktober 2015 16:00 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait

EMERYVILLE, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced findings from two nonclinical studies that demonstrate the potential of ADS-5102...

Vorherige Seite